Detalhe da pesquisa
1.
Spatial predictors of immunotherapy response in triple-negative breast cancer.
Nature
; 621(7980): 868-876, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37674077
2.
Intravenous methylprednisolone pulses in hospitalised patients with severe COVID-19 pneumonia: a double-blind, randomised, placebo-controlled trial.
Eur Respir J
; 60(4)2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35361632
3.
Single Institution trial of anthracycline- and taxane-based chemotherapy for operable breast cancer: The ASTER study.
Breast J
; 25(2): 237-242, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30810258
4.
Everolimus Plus Exemestane in Advanced Breast Cancer: Safety Results of the BALLET Study on Patients Previously Treated Without and with Chemotherapy in the Metastatic Setting.
Oncologist
; 22(6): 648-654, 2017 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-28432226
5.
Antitumor activity and safety profile of weekly carboplatin plus paclitaxel in metastatic breast cancer: a ten-year, monocentric, retrospective study.
Breast Cancer Res Treat
; 165(2): 365-373, 2017 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-28616768
6.
Effects of cytochrome P450 (CYP3A4 and CYP2C19) inhibition and induction on the exposure of selumetinib, a MEK1/2 inhibitor, in healthy subjects: results from two clinical trials.
Eur J Clin Pharmacol
; 73(2): 175-184, 2017 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-27889832
7.
Pharmacokinetics and pharmacogenetics of the MEK1/2 inhibitor, selumetinib, in Asian and Western healthy subjects: a pooled analysis.
Eur J Clin Pharmacol
; 73(6): 717-726, 2017 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-28283692
8.
Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial.
JAMA
; 317(18): 1844-1853, 2017 05 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28492898
9.
Gene expression profiling of circulating tumor cells in breast cancer.
Clin Chem
; 61(1): 278-89, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25411184
10.
¹8F-FLT PET/CT as an imaging tool for early prediction of pathological response in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy: a pilot study.
Eur J Nucl Med Mol Imaging
; 42(6): 818-30, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25673053
11.
Axillary lymph node dissection versus no dissection in patients with T1N0 breast cancer: a randomized clinical trial (INT09/98).
Cancer
; 120(6): 885-93, 2014 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-24323615
12.
Effectiveness of a phone-based nurse monitoring assessment and intervention for chemotherapy-related toxicity: A randomized multicenter trial.
Front Oncol
; 12: 925366, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36185306
13.
Bleeding complications in patients with squamous cell carcinoma of the head and neck.
Head Neck
; 43(9): 2844-2858, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34117666
14.
The Pan-Immune-Inflammation-Value Predicts the Survival of Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Breast Cancer Treated with First-Line Taxane-Trastuzumab-Pertuzumab.
Cancers (Basel)
; 13(8)2021 Apr 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-33921727
15.
Everolimus plus aromatase inhibitors as maintenance therapy after first-line chemotherapy: Final results of the phase III randomised MAIN-A (MAINtenance Afinitor) trial.
Eur J Cancer
; 154: 21-29, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34225066
16.
Antitumor activity and efficacy of shorter versus longer duration of anthracycline-taxane neoadjuvant chemotherapy in stage II-III HER2-negative breast cancer: a 10-year, retrospective analysis.
Ther Adv Med Oncol
; 12: 1758835920970081, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-33335565
17.
A Phase 1 Study of mTORC1/2 Inhibitor BI 860585 as a Single Agent or with Exemestane or Paclitaxel in Patients with Advanced Solid Tumors.
Cancers (Basel)
; 12(6)2020 May 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-32486385
18.
Oral Capecitabine-Vinorelbine is Associated with Longer Overall Survival When Compared to Single-Agent Capecitabine in Patients with Hormone Receptor-Positive Advanced Breast Cancer.
Cancers (Basel)
; 12(3)2020 Mar 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32155941
19.
Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer.
Nat Clin Pract Oncol
; 6(2): 93-104, 2009 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-19107109
20.
Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: Current knowledge, new research directions and therapeutic perspectives.
Crit Rev Oncol Hematol
; 139: 53-66, 2019 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-31112882